MRNA

Moderna Inc

Add to Watchlist

Advanced Chart

26.120

-0.49(-1.841%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

26.880

Open

26.545

VWAP

26.25

Vol

6.61M

Mkt Cap

10.16B

Low

25.890

Amount

173.44M

EV/EBITDA(TTM)

Total Shares

383.24M

5.28B

EV/OCF(TTM)

P/S(TTM)

3.37

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q3

FY2025Q4

FY2026Q1

931.00M

-50%

-2.154

-7279.23%

732.84M

-24.14%

-2.840

-2.4%

160.80M

+48.89%

-2.487

-1.32%

Estimates Revision

The market is revising Downward the revenue expectations for Moderna, Inc. (MRNA) for FY2025, with the revenue forecasts being adjusted by -0.25% over the past three months. During the same period, the stock price has changed by 7.71%.

Revenue Estimates for FY2025

Revise Downward

-0.25%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.43%

In Past 3 Month

Stock Price

Go Up

+7.71%

In Past 3 Month

20 Analyst Rating

84.04% Upside

Wall Street analysts forecast MRNA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRNA is 48.07 USD with a low forecast of 25.00 USD and a high forecast of 198.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

13 Hold

3 Sell

Hold

84.04% Upside

Current: 26.120

Low

25.00

Averages

48.07

High

198.00

84.04% Upside

Current: 26.120

Low

25.00

Averages

48.07

High

198.00

Barclays

Gena Wang

Equal Weight

downgrade

$40 -> $31

2025-08-04

New

Reason

Barclays

Gena Wang

Price Target

$40 -> $31

2025-08-04

New

downgrade

Equal Weight

Reason

Barclays analyst Gena Wang lowered the firm's price target on Moderna to $31 from $40 and keeps an Equal Weight rating on the shares. The company's Q2 outlook cut is due to UK contracting revenue pushed out to Q1 of 2026, the analyst tells investors in a research note. The firm believes Moderna's further cost cuts will keep its goal intact for breakeven in 2028.

BofA

Tim Anderson

Underperform

downgrade

$25 -> $24

2025-08-04

New

Reason

BofA

Tim Anderson

Price Target

$25 -> $24

2025-08-04

New

downgrade

Underperform

Reason

BofA analyst Tim Anderson lowered the firm's price target on Moderna to $24 from $25 and keeps an Underperform rating on the shares. Q2 total revenues were ahead of expectations, led entirely by COVID, notes the analyst, who also points out that 2025 revenue guidance was trimmed to $1.5B-$2.2B from $1.5B-$2.5B, reflecting a shift in vaccine delivery timing to the United Kingdom.

BofA

Underperform

downgrade

$26 -> $25

2025-07-22

Reason

BofA

Price Target

$26 -> $25

2025-07-22

downgrade

Underperform

Reason

BofA lowered the firm's price target on Moderna to $25 from $26 and keeps an Underperform rating on the shares. For Q1, the firm made no material changes to its model ahead of earnings, but for 2025 its revenue forecast has decreased by 10%, primarily due to lower U.S. COVID sales as a result of updated recommendations, the analyst tells investors in a preview.

Bernstein

Market Perform

downgrade

$39 -> $28

2025-04-24

Reason

Bernstein

Price Target

$39 -> $28

2025-04-24

downgrade

Market Perform

Reason

Bernstein lowered the firm's price target on Moderna to $28 from $39 given recent political headwinds for the stock, while keeping a Market Perform rating on the shares. The firm says that little to no revenue is anticipated for Moderna in Q1. However, Bernstein will be looking closely for updates on pipeline and any changes to expectations given the vaccines and mRNA sentiment from the new HHS secretary.

BofA

Underperform

downgrade

$32 -> $26

2025-04-24

Reason

BofA

Price Target

$32 -> $26

2025-04-24

downgrade

Underperform

Reason

BofA lowered the firm's price target on Moderna to $26 from $32 and keeps an Underperform rating on the shares. For 2025, the firm's revenue forecast decreases by 1% and EPS view is flat. For the later 2020's, its total revenue estimates decrease by 10 to 12%, primarily due to lower sales from mRNA-1083 given the firm's lower probability-of-success assumption and mRESVIA given its lower share assumption, the analyst tells investors.

Morgan Stanley

Matthew Harrison

Hold

Maintains

$39 → $32

2025-04-09

Reason

Morgan Stanley

Matthew Harrison

Price Target

$39 → $32

2025-04-09

Maintains

Hold

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Moderna Inc (MRNA.O) is -2.61, compared to its 5-year average forward P/E of -27.41. For a more detailed relative valuation and DCF analysis to assess Moderna Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-27.41

Current PE

-2.61

Overvalued PE

127.19

Undervalued PE

-182.01

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

3.06

Current EV/EBITDA

-1.02

Overvalued EV/EBITDA

32.65

Undervalued EV/EBITDA

-26.54

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Fair

5Y Average PS

6.58

Current PS

5.39

Overvalued PS

10.08

Undervalued PS

3.08

Financials

Annual

Quarterly

FY2025Q2

YoY :

-41.08%

142.00M

Total Revenue

FY2025Q2

YoY :

-35.58%

-869.00M

Operating Profit

FY2025Q2

YoY :

-35.50%

-825.00M

Net Income after Tax

FY2025Q2

YoY :

-36.04%

-2.13

EPS - Diluted

FY2025Q2

YoY :

-36.68%

-922.00M

Free Cash Flow

FY2025Q2

YoY :

-26.05%

42.96

Gross Profit Margin - %

FY2025Q2

-113.71

FCF Margin - %

FY2025Q2

YoY :

+9.47%

-580.99

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

8.7K

USD

3-6

Months

0.0

USD

6-9

Months

18.4K

USD

0-12

Months

238.2K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 437.15% over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

171.4K

Volume

6-9

Months

31.9K

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

1.3M

Volume

Months

6-9

1.2M

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

8.0K

USD

6-9

Months

16.0K

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

8.0K

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

8.7K

USD

3-6

Months

0.0

USD

6-9

Months

18.4K

USD

0-12

Months

238.2K

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

MRNA News & Events

Events Timeline

2025-08-05 (ET)

2025-08-05

19:09:51

HHS begins winding down mRNA vaccine development under BARDA

2025-08-01 (ET)

2025-08-01

07:14:25

Moderna now sees FY25 revenue $1.5B-$2.2B, consensus $2.07B

2025-08-01

07:13:26

Moderna reports Q2 EPS ($2.13), consensus ($2.97)

News

2.0

08-08TipRanks

SPY ETF News, 8/8/2025

2.0

08-08TipRanks

VOO ETF News, 8/8/2025

4.0

08-07Yahoo Finance

Influenza Vaccine Market Research Report 2025-2030 Featuring GSK, Abbott, Pfizer, AstraZeneca, Sanofi, Moderna, CSL, Emergent BioSolutions, BIKEN, Serum Institute of India, Sinovac, GC Biopharma